ReviewClinical and translational medicine2026
Remodelling the tumour microenvironment and beyond: ERO1A as a multifaceted regulator and emerging therapeutic target in cancer.
Review in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundEndoplasmic reticulum oxidoreductase 1α (ERO1A) is the core engine of oxidative protein folding in the endoplasmic reticulum (ER), playing a central role in maintaining ER redox homeostasis and modulating the unfolded protein response (UPR). Its aberrant overexpression in multiple solid tumors has established ERO1A as a critical regulator of tumor progression, microenvironment remodeling, and therapy resistance, positioning it as an emerging therapeutic target in precision oncology. MAIN BODY: This review systematically synthesizes the structural biology, catalytic mechanisms, and regulatory networks of ERO1A, encompassing transcriptional control, post-translational modifications, and compensatory alternative oxidases. We detail the multidimensional oncogenic functions of ERO1A, including intracellular promotion of proliferation, apoptosis resistance, migration, invasion, and epithelial-mesenchymal transition, as well as extracellular remodeling of the tumor microenvironment via VEGF-driven angiogenesis, PD-L1-mediated immune evasion, metabolic reprogramming, and induction of CD8
conclusionERO1A represents a promising yet challenging therapeutic node that connects ER stress adaptation with tumor pathogenesis. Overcoming the limitations of current inhibitors-particularly poor isoform selectivity, off-target effects, and pharmacokinetic deficiencies-through structure-guided optimization, allosteric modulation, or protein degradation technologies will be essential for clinical translation. Future efforts should focus on biomarker-driven patient stratification and rational combination with immunotherapies or conventional chemotherapies to maximize therapeutic benefit.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.